Mefenamic acid

Generic Name: Mefenamic acid

Brand Names: Mefenamic, Ponstel

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₅NO_₂

CAS Number: 61-68-7

Unique Ingredient Identifier: 367589PJ2C

Background: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

Indication: For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.

Associated Conditions: Mild pain, Primary Dysmenorrhoea, Gastrointestinal cramping, Moderate Pain

Clinical Trials

Management of Abnormal Uterine Bleeding

Not Applicable

Recruiting

Conditions: Abnormal Uterine Bleeding

Interventions: Drug: Mefenamic acid 500 mg

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Egymedicalpedia

Target Recruit Count: 130

Registration Number: NCT06369012

Locations: 🇪🇬
Ain Shams University Hospitals, Cairo, Egypt

A Trial Investigating Lu AF28996 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Lu AF28996
Drug: Amoxicillin/clavulanic acid
Drug: Acetylsalicylic Acid
Drug: Mefenamic Acid

First Posted Date: 2024-02-26

Last Posted Date: 2024-06-11

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 22

Registration Number: NCT06277609

Locations: 🇺🇸
Covance Dallas CRU, Dallas, Texas, United States

A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Soticlestat
Drug: Mefenamic acid
Drug: Itraconazole

First Posted Date: 2021-10-01

Last Posted Date: 2023-10-03

Lead Sponsor: Takeda

Target Recruit Count: 28

Registration Number: NCT05064449

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

Phase 1

Completed

Conditions: Drug Interaction

Interventions: Drug: ecopipam HCL
Drug: Divalproex Sodium ER
Drug: Mefenamic acid

First Posted Date: 2021-05-26

Last Posted Date: 2021-07-22

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 38

Registration Number: NCT04902105

Locations: 🇺🇸
Syneos Health Clinical Research Services, LLC., Miami, Florida, United States

Preemptive Analgesia for Primary Dysmenorrhoea

Phase 2

Completed

Conditions: Primary Dysmenorrhea

Interventions: Drug: preemptive mefenamic acid
Drug: mefenamic acid

First Posted Date: 2017-10-27

Last Posted Date: 2017-12-19

Lead Sponsor: Hanan Nabil

Target Recruit Count: 84

Registration Number: NCT03323671

Locations: 🇪🇬
Mansoura University, Mansourah, Egypt

Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Sotagliflozin (SAR439954)
Drug: Mefenamic acid

First Posted Date: 2017-03-03

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT03070678

Locations: 🇫🇷
Investigational site 250001, Gières, France

Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

Phase 3

Completed

Conditions: Heavy Menstrual Bleeding
Improve Quality of Life

Interventions: Drug: medroxyprogesterone acetate (progest)
Drug: mefenamic acid (ponstan forte)
Drug: combined contraceptive pills (microcept)

First Posted Date: 2016-10-25

Last Posted Date: 2021-06-04

Lead Sponsor: Assiut University

Target Recruit Count: 240

Registration Number: NCT02943655

Locations: 🇪🇬
Ahmed Abbas, Assiut, Cairo, Egypt

Efficacy of Different Drugs to Control Post Root Canal Treatment Pain

Phase 2

Completed

Conditions: Postoperative Pain
Irreversible Pulpitis
Pain

Interventions: Procedure: Root Canal Treatment
Drug: Paracetamol
Drug: Ibuprofen
Drug: Mefenamic acid
Drug: Diclofenac

First Posted Date: 2015-04-15

Last Posted Date: 2015-04-15

Lead Sponsor: University of Khartoum

Target Recruit Count: 170

Registration Number: NCT02417337

Locations: 🇸🇩
University of Khartoum, Faculty of Dentistry,, Khartoum, Sudan

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

Phase 2

Completed

Conditions: Dysmenorrhea

Interventions: Drug: Mefenamic acid 500 mg
Drug: Meloxicam 7.5 mg
Drug: Meloxicam 15 mg
Drug: Placebo matching 7.5 mg meloxicam
Drug: Placebo matching 500 mg mefenamic acid
Drug: Placebo matching 15 mg meloxicam

First Posted Date: 2014-07-08

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 337

Registration Number: NCT02183025

DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

Phase 2

Completed

Conditions: Endometrioma
Visual Analogue Pain Scale: Moderate or Severe Pain

Interventions: Drug: DLBS1442 200
Drug: DLBS1442 100
Drug: Mefenamic acid

First Posted Date: 2013-09-13

Last Posted Date: 2022-01-27

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 60

Registration Number: NCT01942122

Locations: 🇮🇩
Yasmin Clinic, Dr. Cipto Mangunkusumo Hospital (Kencana), Jakarta Pusat, Jakarta, Indonesia
🇮🇩
Department of Obstetrics and Gynecology, RSUP Persahabatan, Jakarta Pusat, Jakarta, Indonesia
🇮🇩
Department of Obstetrics and Gynecology RSUP Fatmawati, Jakarta, Indonesia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy